Entresto combines sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, to enhance heart failure treatment. Sacubitril inhibits neprilysin, leading to increased levels of natriuretic peptides, which promote vasodilation and sodium excretion. Valsartan blocks the effects of angiotensin II, reducing vasoconstriction and aldosterone secretion. Together, they improve cardiovascular outcomes by lowering blood pressure, decreasing strain on the heart, and enhancing blood flow. Entresto is indicated for adult patients with chronic heart failure to reduce the risk of cardiovascular death and hospitalization. . Please Note that product description, color, ingredients, package and other information maybe different from the original pack kindly check the product for more accurate details.
